We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Medpace (MEDP - Free Report) ended the recent trading session at $602.90, demonstrating a -2.84% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. On the other hand, the Dow registered a gain of 0.49%, and the technology-centric Nasdaq increased by 0.45%.
Heading into today, shares of the provider of outsourced clinical development services had gained 4.94% over the past month, outpacing the Medical sector's loss of 4.26% and the S&P 500's gain of 0.84%.
Analysts and investors alike will be keeping a close eye on the performance of Medpace in its upcoming earnings disclosure. The company's earnings report is set to go public on October 21, 2026. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $708.75 million, indicating a 7.4% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $17.54 per share and revenue of $2.84 billion. These totals would mark changes of +14.79% and +12.38%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Medpace. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medpace presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Medpace is currently trading at a Forward P/E ratio of 35.38. This valuation marks a premium compared to its industry average Forward P/E of 16.59.
One should further note that MEDP currently holds a PEG ratio of 2.77. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Services industry currently had an average PEG ratio of 1.62 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 111, which puts it in the top 46% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
Medpace (MEDP - Free Report) ended the recent trading session at $602.90, demonstrating a -2.84% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. On the other hand, the Dow registered a gain of 0.49%, and the technology-centric Nasdaq increased by 0.45%.
Heading into today, shares of the provider of outsourced clinical development services had gained 4.94% over the past month, outpacing the Medical sector's loss of 4.26% and the S&P 500's gain of 0.84%.
Analysts and investors alike will be keeping a close eye on the performance of Medpace in its upcoming earnings disclosure. The company's earnings report is set to go public on October 21, 2026. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $708.75 million, indicating a 7.4% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $17.54 per share and revenue of $2.84 billion. These totals would mark changes of +14.79% and +12.38%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Medpace. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medpace presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Medpace is currently trading at a Forward P/E ratio of 35.38. This valuation marks a premium compared to its industry average Forward P/E of 16.59.
One should further note that MEDP currently holds a PEG ratio of 2.77. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Services industry currently had an average PEG ratio of 1.62 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 111, which puts it in the top 46% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.